Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Boston Scientific May Now Have The Strongest Pipeline In Company History

Courtesy of Benzinga.

Boston Scientific May Now Have The Strongest Pipeline In Company History

Canaccord Genuity said in a Tuesday note Boston Scientific Corporation (NYSE: BSX) enjoys the most robust pipeline in its long, storied history. The firm also said the company is set to further augment the proportion of sales derived from faster-growth markets, many of which sport tailwinds.

The firm initiated coverage of Boston Scientific with a Buy rating and a Street-high price target of $36 for the shares.

Analyst Jason Mills said the company is primed to deliver top- and bottom-line growth above its peer group over the next few years, given its compelling portfolio of differentiated products.

The products include Watchman, LAAC, S-ICD, Synergy DES and Lotus/Acurate TAVR, while the company also offers several differentiated technologies in its dominant Med-Surg business.

See also: This Healthcare ETF Continues Beating Higher

The analyst thinks the stock will outperform large-cap med-tech peers over the next three years through three drivers, which fundamentally comprise his bullish thesis.

    1. Boston Scientific will deliver faster organic growth versus large-cap med-tech peer group. Canaccord Genuity estimates organic revenue growth of 7.8 percent through 2020 compared to 7 percent for large-cap peers.
    2. The company will deliver operating margin expansion, suggesting faster earnings per share growth versus peer group through 2018, at least.
    3. The firm expects the company to leverage a relatively unencumbered balance sheet in 2018-2021, allowing the company to consummate deals capable of augmenting growth and margins beyond organic means.

    The firm said the company would spend about 90 percent of the $6.6 billion in free cash flow it estimates for the 2018-2020 timeframe, on M&A or returning cash to shareholders compared to 17 percent in the 2015-2017 timeframe.

    Latest Ratings for BSX

    Date Firm Action From To
    Oct 2017 Canaccord Genuity Initiates Coverage On Buy
    May 2017 Goldman Sachs Initiates Coverage On Neutral
    Oct 2016 Citigroup Maintains Buy

    View More Analyst Ratings for BSX


    View the Latest Analyst Ratings

    Posted-In: Analyst Color Long Ideas Health Care Initiation Analyst Ratings Tech Trading Ideas General Best of Benzinga


    Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





    You must be logged in to make a comment.
    You can sign up for a membership or get a FREE Daily News membership or log in

    Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

    Click here to see some testimonials from our members!